Table 3d. Therapeutic Management of Hospitalized Pediatric Patients With MIS-C
Last Updated: December 28, 2022
|Patient Condition||Panel’s Recommendations|
|MIS-C||Initial treatment for MIS-C includes both immunomodulatory and antithrombotic therapy.|
Initial Immunomodulatory Therapy
|Each recommendation in the Guidelines receives 2 ratings that reflect the strength of the recommendation and the quality of the evidence that supports it. See Guidelines Development for more information.|
a Duration of therapy may vary. For more information, see Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A]).
b In certain patients with severe illness, intensification therapy may include dual therapy with higher-dose glucocorticoids and infliximab or anakinra. Anakinra and infliximab should not be given in combination..
c Infliximab should not be used in patients with macrophage activation syndrome.
Key: CAA = coronary artery aneurysm; IBW = ideal body weight; IV = intravenous; IVIG = intravenous immunoglobulin; LV = left ventricular; MIS-C = multisystem inflammatory syndrome in children; PO = oral; SUBQ = subcutaneously